Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool

The main objective of this investigation was to develop an in vitro–in vivo correlation (IVIVC) for immediate release candesartan cilexetil formulations by designing an in vitro dissolution test to be used as development tool. The IVIVC could be used to reduce failures in future bioequivalence studi...

Full description

Bibliographic Details
Main Authors:	Andrés Figueroa-Campos, Bárbara Sánchez-Dengra, Virginia Merino, Arik Dahan, Isabel González-Álvarez, Alfredo García-Arieta, Marta González-Álvarez, Marival Bermejo
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Pharmaceutics
Subjects:	candesartan cilexetil IVIVC bioequivalence BCS predictive in vivo-dissolution
Online Access:	https://www.mdpi.com/1999-4923/12/7/633

Similar Items

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
by: Omar Y. Mady, et al.
Published: (2021-08-01)

Oral nanoemulsions of candesartan cilexetil: formulation, characterization and in vitro drug release studies
by: Halah Hussein Ali, et al.
Published: (2017-06-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Response surface based optimization of system variables for liquid chromatographic analysis of candesartan cilexetil
by: Jagdish V. Manwar, et al.
Published: (2017-01-01)

Novel Combination for Self-Nanoemulsifying Drug Delivery System of Candesartan Cilexetil
by: Safa F. Mekhilef, et al.
Published: (2018-12-01)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
by: AbuElfadl A, et al.
Published: (2021-08-01)

Identification of Candesartan Cilexetil-L-Arginine Co-amorphous Formation and Its Solubility Test
by: Fikri Alatas, et al.
Published: (2022-02-01)

Effects of combination of AT1-antagonist candesartan cilexetil and ASE-inhibitors in patients with congestive heart failure
by: Gašanin Edis, et al.
Published: (2013-01-01)

Development and validation of a dissolution test with reversed-phase high performance liquid chromatographic analysis for Candesartan cilexetil in tablet dosage forms
by: Vairappan Kamalakkannan, et al.
Published: (2016-09-01)

Technological approaches to improve the bioavailability of the poor soluble substance Candesartan Cilexetil in mini-tablets
by: K. M. Tserkovnaya, et al.
Published: (2023-09-01)

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment
by: Moon-Seung Soh, et al.
Published: (2024-10-01)

Modelling Drying Time of Candesartan Cilexetil Powder Using Computational Intelligence Technique
by: Sonia Keskes, et al.
Published: (2021-03-01)

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration
by: Walid Anwar, et al.
Published: (2020-10-01)

Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients
by: Isabel González-Álvarez, et al.
Published: (2022-11-01)

Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction
by: Gwo‐Jyh Chang, et al.
Published: (2022-08-01)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
by: Surendra Poudel, et al.
Published: (2021-04-01)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
by: Zimlichman R
Published: (2011-12-01)

In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium
by: Marival Bermejo, et al.
Published: (2020-06-01)

An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl
by: J.R. Aravindaraj, et al.
Published: (2014-10-01)

An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl
by: Aravindaraj, J.R., et al.
Published: (2014-09-01)

Multi-Compartmental Dissolution Method, an Efficient Tool for the Development of Enhanced Bioavailability Formulations Containing Poorly Soluble Acidic Drugs
by: Miklós Tamás Katona, et al.
Published: (2023-02-01)

Candesartan cilexetil in cardiovascular prevention
by: A. Ya. Ivleva
Published: (2007-12-01)

Biorelevant dissolution of candesartan cilexetil
by: Lucie Gruberová, et al.
Published: (2017-03-01)

In Vivo Relevance of a Biphasic In Vitro Dissolution Test for the Immediate Release Tablet Formulations of Lamotrigine
by: Tuba Incecayir, et al.
Published: (2023-10-01)

In vivo dissolution of poorly water-soluble drugs: Proof of concept based on fluorescence bioimaging
by: Yinqian Yang, et al.
Published: (2021-04-01)

In Vitro–In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of Its Metabolite
by: Constantin Mircioiu, et al.
Published: (2019-07-01)

An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products
by: Isabel Gonzalez-Alvarez, et al.
Published: (2021-04-01)

Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116
by: Testen Ana, et al.
Published: (2019-03-01)

Determination of Candesartan in Human Plasma using Liquid Chromatography - Tandem Mass Spectrometry
by: Vanja Forjan, et al.
Published: (2016-02-01)

Oral solid self-nanoemulsifying drug delivery systems of candesartan citexetil: formulation, characterization and in vitro drug release studies
by: Halah Hussein Ali, et al.
Published: (2017-06-01)

Pediatric Biopharmaceutical Classification Systems (pBCS)
by: Justyna Srebro, et al.
Published: (2023-10-01)

ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries
by: Claudia Miranda, et al.
Published: (2021-03-01)

Establishment and Validation of a New Co-Culture for the Evaluation of the Permeability through the Blood–Brain Barrier in Patients with Glioblastoma
by: Bárbara Sánchez-Dengra, et al.
Published: (2023-05-01)

DISSOLUTION TEST FOR MIANSERIN HYDROCHLORIDE IN TABLETS
by: Letícia Lenz Sfair, et al.
Published: (2019-12-01)

In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation
by: Marcelo Dutra Duque, et al.
Published: (2019-05-01)

Candesartan in treating hypertension
by: L O Minushkina
Published: (2014-03-01)

Solid State Stability and Kinetics of Degradation for Candesartan—Pure Compound and Pharmaceutical Formulation
by: Valentina Buda, et al.
Published: (2020-01-01)

Oral Gels as an Alternative to Liquid Pediatric Suspensions Compounded from Commercial Tablets
by: Monika Trofimiuk, et al.
Published: (2024-09-01)

Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process
by: Jonattan Gallegos-Catalán, et al.
Published: (2021-07-01)

In vitro-in vivo correlation (IVIVC) of different parameters of dosage form
by: Shazia Ashraf, et al.
Published: (2021-07-01)